UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 691

Sortiert nach

Inflammatory Bowel Disease as a Risk Factor for Colorectal Cancer

Digestive diseases (Basel), 2010-01, Vol.28 (4-5), p.619-624

Lukas, Milan

2010

Link zum Volltext

Verfügbarkeit prüfen

Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial

Gastroenterology (New York, N.Y. 1943), 2006-02, Vol.130 (2), p.323-333

2006

Link zum Volltext

Verfügbarkeit prüfen

Pentane and other volatile organic compounds, including carboxylic acids, in the exhaled breath of patients with Crohn's disease and ulcerative colitis

Journal of breath research, 2018-01, Vol.12 (1), p.016002-016002

2018

Link zum Volltext

Verfügbarkeit prüfen

Biosimilars: A Multidisciplinary Perspective

Clinical therapeutics, 2016-05, Vol.38 (5), p.1238-1249

2016

Link zum Volltext

Verfügbarkeit prüfen

Tu1786 SUBCUTANEOUS INFLIXIMAB: MIDTERM TREATMENT OUTCOMES IN PATIENTS WITH REFRACTORY CROHN'S DISEASE AFTER MULTIPLE TREATMENT FAILURES

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-1127-S-1128

2023

Link zum Volltext

Verfügbarkeit prüfen

Serum TGF-β1 and CD14 Predicts Response to Anti-TNF-α Therapy in IBD

Journal of immunology research, 2023-01, Vol.2023, p.1-16

2023

Link zum Volltext

Verfügbarkeit prüfen

Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy

Frontiers in cellular and infection microbiology, 2023-01, Vol.12, p.1064537-1064537

2023

Link zum Volltext

Verfügbarkeit prüfen

Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease

Biologicals, 2016-01, Vol.44 (1), p.33-36

2016

Link zum Volltext

Verfügbarkeit prüfen

Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy

Cells (Basel, Switzerland), 2021-11, Vol.10 (11), p.3188

2021

Link zum Volltext

Verfügbarkeit prüfen

Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study

Therapeutic advances in gastroenterology, 2021, Vol.14, p.175628482110327-17562848211032790

2021

Link zum Volltext

Verfügbarkeit prüfen

Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases

Intestinal research, 2020, 18(1), , pp.34-44

2020

Link zum Volltext

Verfügbarkeit prüfen

Effect of COVID-19 pandemic on the workflow of endoscopy units: an international survey

Therapeutic advances in gastroenterology, 2021-01, Vol.14, p.17562848211006678-17562848211006678

2021

Link zum Volltext

Verfügbarkeit prüfen

FROM RESISTANCE TO RESPONSE: 52 WEEKS OF SUBCUTANEOUS INFLIXIMAB IN REFRACTORY CROHN'S DISEASE PATIENTS AFTER THE MULTIPLE TREATMENT FAILURES

Gastroenterology (New York, N.Y. 1943), 2024-02, Vol.166 (3), p.S117

2024

Link zum Volltext

Verfügbarkeit prüfen

EP1285: POINT-OF-CARE MEASUREMENT OF INFLIXIMAB AND ADALIMUMAB TROUGH LEVELS BY THE FLUORESCENCE RESONANCE ENERGY TRANSFER (FRET) ASSAY

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-1086-S-1087

2022

Link zum Volltext

Verfügbarkeit prüfen

ENDOSCOPIC STRICTUROTOMY – A NOVEL THERAPEUTIC MODALITY FOR IBD-RELATED STRICTURES: FIRST EUROPEAN EXPERIENCE

Gastrointestinal endoscopy, 2022-06, Vol.95 (6), p.AB189-AB190

2022

Link zum Volltext

Verfügbarkeit prüfen

ENDOSCOPIC STRICTUROTOMY – A NOVEL THERAPEUTIC MODALITY FOR IBD-RELATED STRICTURES: FIRST EUROPEAN EXPERIENCE

Gastroenterology (New York, N.Y. 1943), 2022-02, Vol.162 (3), p.S40-S41

2022

Link zum Volltext

Verfügbarkeit prüfen

Quantification of pentane in exhaled breath, a potential biomarker of bowel disease, using selected ion flow tube mass spectrometry

Rapid communications in mass spectrometry, 2013-09, Vol.27 (17), p.1983-1992

2013

Link zum Volltext

Verfügbarkeit prüfen

Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis

BMC gastroenterology, 2022-06, Vol.22 (1), p.291-291, Article 291

2022

Link zum Volltext

Verfügbarkeit prüfen

Barriers in inflammatory bowel disease care in Central and Eastern Europe: a region-specific analysis

Therapeutic Advances in Gastroenterology, 2023-01, Vol.16, p.17562848231174290-17562848231174290

2023

Link zum Volltext

Verfügbarkeit prüfen

Su1030 ENDOSCOPIC STRICTUROTOMY – A NOVEL THERAPEUTIC MODALITY FOR IBD-RELATED STRICTURES: FIRST EUROPEAN EXPERIENCE

Gastrointestinal endoscopy, 2020-06, Vol.91 (6), p.AB273-AB273

2020

Link zum Volltext

Verfügbarkeit prüfen

ANTI-SARS-COV-2 VACCINATION AND ANTIBODY RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON IMMUNE-MODIFYING THERAPY. PROSPECTIVE SINGLE TERTIARY CENTER STUDY ON 602 IBD PATIENTS

Gastroenterology (New York, N.Y. 1943), 2022-02, Vol.162 (3), p.S101-S102

2022

Link zum Volltext

Verfügbarkeit prüfen

Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials

BMC gastroenterology, 2024-03, Vol.24 (1), p.121-121

2024

Link zum Volltext

Verfügbarkeit prüfen

Fecal Microbial Transplantation versus Mesalamine Enema for Treatment of Active Left-Sided Ulcerative Colitis—Results of a Randomized Controlled Trial

Journal of clinical medicine, 2021-06, Vol.10 (13), p.2753

2021

Link zum Volltext

Verfügbarkeit prüfen

SUBCUTANEOUS INFLIXIMAB IN REFRACTORY CROHN’S DISEASE PATIENTS AFTER THE MULTIPLE TREATMENT FAILURES - SHORT TREATMENT OUTCOMES

Gastroenterology (New York, N.Y. 1943), 2023-04, Vol.164 (4), p.S97-S97

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 691

Suche als RSS-Feed

Aktive Filter

KollektionRCN full-text journals@Ovid

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(602)
Mit Volltextzugriff
(665)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(381)
Life Sciences & Biomedicine
(195)
Technology
(141)
Physical Sciences
(108)
Humans
(90)
Chemistry
(74)
Materials Science
(57)
Engineering
(53)
Gastroenterology And Hepatology
(43)
Female
(40)
Male
(39)
Materials Science, Multidisciplinary
(38)
Chemistry, Multidisciplinary
(36)
Physics
(35)
Adult
(33)
Biochemistry & Molecular Biology
(30)
Middle Aged
(28)
Animals
(27)
Computer Science
(25)
Science & Technology - Other Topics
(25)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Inflammatory Bowel Disease as a Risk Factor for Colorectal Cancer

Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial

Association between ustekinumab therapy and changes in specific anti-microbial response, serum biomarkers, and microbiota composition in patients with IBD: A pilot study

Pentane and other volatile organic compounds, including carboxylic acids, in the exhaled breath of patients with Crohn's disease and ulcerative colitis

Biosimilars: A Multidisciplinary Perspective

Tu1786 SUBCUTANEOUS INFLIXIMAB: MIDTERM TREATMENT OUTCOMES IN PATIENTS WITH REFRACTORY CROHN'S DISEASE AFTER MULTIPLE TREATMENT FAILURES

Serum TGF-β1 and CD14 Predicts Response to Anti-TNF-α Therapy in IBD

Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy

Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease

Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy

Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study

Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases

Effect of COVID-19 pandemic on the workflow of endoscopy units: an international survey

FROM RESISTANCE TO RESPONSE: 52 WEEKS OF SUBCUTANEOUS INFLIXIMAB IN REFRACTORY CROHN'S DISEASE PATIENTS AFTER THE MULTIPLE TREATMENT FAILURES

EP1285: POINT-OF-CARE MEASUREMENT OF INFLIXIMAB AND ADALIMUMAB TROUGH LEVELS BY THE FLUORESCENCE RESONANCE ENERGY TRANSFER (FRET) ASSAY

ENDOSCOPIC STRICTUROTOMY – A NOVEL THERAPEUTIC MODALITY FOR IBD-RELATED STRICTURES: FIRST EUROPEAN EXPERIENCE

ENDOSCOPIC STRICTUROTOMY – A NOVEL THERAPEUTIC MODALITY FOR IBD-RELATED STRICTURES: FIRST EUROPEAN EXPERIENCE

Quantification of pentane in exhaled breath, a potential biomarker of bowel disease, using selected ion flow tube mass spectrometry

Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis

Barriers in inflammatory bowel disease care in Central and Eastern Europe: a region-specific analysis

Su1030 ENDOSCOPIC STRICTUROTOMY – A NOVEL THERAPEUTIC MODALITY FOR IBD-RELATED STRICTURES: FIRST EUROPEAN EXPERIENCE

ANTI-SARS-COV-2 VACCINATION AND ANTIBODY RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON IMMUNE-MODIFYING THERAPY. PROSPECTIVE SINGLE TERTIARY CENTER STUDY ON 602 IBD PATIENTS

Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials

Fecal Microbial Transplantation versus Mesalamine Enema for Treatment of Active Left-Sided Ulcerative Colitis—Results of a Randomized Controlled Trial

SUBCUTANEOUS INFLIXIMAB IN REFRACTORY CROHN’S DISEASE PATIENTS AFTER THE MULTIPLE TREATMENT FAILURES - SHORT TREATMENT OUTCOMES

Aktive Filter

Suchergebnisse filtern